REVIEW
Published on 14 Feb 2022
Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
doi 10.3389/fphar.2022.774170
- 15,998 views
- 28 citations
- Frontiers in Pharmacology
- Drugs Outcomes Research and Policies
- Research Topics
- Evidence-based Advances in the Knowledge and Management of Adverse Events of Immunotherapy for Cancer
Evidence-based Advances in the Knowledge and Management of Adverse Events of Immunotherapy for Cancer
10k
Total downloads
37k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 24 Nov 2021
Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
doi 10.3389/fphar.2021.797852
- 3,370 views
- 9 citations
ORIGINAL RESEARCH
Published on 09 Nov 2021
Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
doi 10.3389/fphar.2021.747416
- 1,431 views
REVIEW
Published on 08 Nov 2021
Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
doi 10.3389/fphar.2021.747075
- 1,980 views
- 6 citations
REVIEW
Published on 01 Nov 2021
Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation
doi 10.3389/fphar.2021.746853
- 2,444 views
- 19 citations
SYSTEMATIC REVIEW
Published on 12 Aug 2021
Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
doi 10.3389/fphar.2021.699892
- 2,267 views
- 8 citations
ORIGINAL RESEARCH
Published on 02 Jul 2021
Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
doi 10.3389/fphar.2021.663088
- 3,277 views
- 25 citations
